Please assess the completion status of the following clinical trial:

Trial Title: Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-infected HIV infection will be confirmed by two different rapid tests (as per South African national Department of Health guidelines) and an HIV viral load test.~2. CD4 count \< 100/μL One CD4 count taken within 3 months prior to enrolment less than 100/μL will qualify, even if other CD4 counts are greater than 100/μL~3. ART-naïve Patients who report having been treated with triple drug or dual drug ART previously will be excluded. Single dose nevirapine or short term AZT monotherapy for PMTCT is not an exclusion.~4. Confirmed diagnosis of TB (smear, culture, Xpert MTB/RIF test or compatible histology) or strong clinical and radiological evidence of TB with symptomatic response to TB treatment~5. On TB treatment for less than 30 days prior to study entry.~6. Eligible for ART and patient consents to starting ART within 30 days of starting TB treatment.~7. Written informed consent for trial~Exclusion Criteria:~1. Kaposi's sarcoma (KS) A thorough examination for KS lesions will be performed and any suspicious lesion will be biopsied. Any history of treatment for KS will also be an exclusion.~2. Pregnant All female participants of child-bearing potential will have a pregnancy test performed prior to enrollment and will be counseled to use to two reliable methods of contraception for the duration of the trial.~3. \<18 years old~4. TB meningitis or tuberculoma at TB diagnosis~5. Clinical syndrome of pericardial TB at TB diagnosis (a pericardial effusion noted on ultrasound scan alone is not an exclusion criterion)~6. Rifampicin-resistant TB diagnosed by Xpert MTB/RIF test or a drug susceptibility test performed on a culture isolate.~7. On corticosteroids for another indication or on any other immunosuppressive medication within the past 7 days.~8. Uncontrolled diabetes mellitus~9. The following abnormal laboratory values:~   Alanine aminotransferase \> 200 IU/l Absolute neutrophil count \< 500/mm3~10. Not on standard intensive phase TB treatment (Rifampicin, isoniazid, pyrazinamide and ethambutol)~11. Poor clinical response to TB treatment prior to ART as judged by the clinical investigators.~12. Hepatitis B surface antigen positive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prednisone (Type: EXPERIMENTAL): Prednisone oral tablets 40mg daily for 2 weeks followed by 20mg daily for 2 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oral tablets 40mg daily for 2 weeks followed by 20mg daily for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).